US Pharma MarketingCellCentric raises $220M to get multiple myeloma pill to market
CellCentric has reeled in a $220 million Series D to help it address multiple myeloma patients who have exhausted all other treatment options. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options.
The 22-year-old transatlantic biotech has collected a $220 million Series D to finish its ...
Source: Endpoints News